Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC By Ogkologos - September 7, 2026 58 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-671 study after 5 years of follow-up Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR How to Get Started With Meditation During Cancer June 21, 2022 EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... April 7, 2022 New plan unveiled to tackle Scotland’s cancer crisis June 16, 2023 Medicare Advantage Plans: Read the Fine Print November 16, 2020 Load more HOT NEWS This 11-Year-Old Is Starting College Next Year With A Plan To... FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL Reflections on Progress and Partnership at ASCO 2026 Selumetinib Continues to Show Promise in Children with NF1
